Editorial: Combination therapies in cancer treatment: enhancing efficacy and reducing resistance

The clinical potential of such immune-oncology doublets is exemplified by the metaanalysis Efficacy and safety of programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) inhibitors combined with tyrosine kinase inhibitors as first-line treatment for hepatocellular carcinoma. This study found that combining PD-1/PD-L1 inhibitors with tyrosine kinase inhibitors significantly improved progression-free survival and objective response rate in patients with unresectable hepatocellular carcinoma, particularly among Asian patients and those infected with hepatitis B virus, without an unacceptable increase in severe adverse events. In a complementary real-world setting, Real-world analysis of immunochemotherapy in recurrent small-cell lung cancer: opportunities for second-line approaches showed that extending immunochemotherapy beyond first-line treatment can offer clinically meaningful benefit in recurrent small-cell lung cancer, highlighting how combination strategies may reshape treatment paradigms even in aggressive, traditionally chemo-sensitive malignancies.A particularly notable contribution in this Topic is the work Activation of the STING pathway potentiates the antitumor efficacy of doxorubicin in soft-tissue sarcoma. Soft-tissue sarcomas are prototypical "cold" tumors with sparse lymphocytic infiltrates and limited responsiveness to immunotherapy. By combining the DNA-damaging agent doxorubicin with deliberate activation of the STING (Stimulator of Interferon Genes) pathway, the authors demonstrate that chemotherapy-induced release of tumor DNA into the cytosol can be harnessed to trigger cGAS-STING signaling, type I interferon production, and enhanced recruitment and activation of effector immune cells. This dual-action approach not only amplifies the direct cytotoxicity of doxorubicin but also remodels the tumor microenvironment toward an inflamed, T cell-permissive state, providing a compelling blueprint for transforming immunologically "cold" sarcomas into "hot" tumors amenable to additional immunotherapeutic interventions.Beyond systemic antibodies and innate immune modulators, innovative cell-based strategies aim to broaden and deepen antitumor immune responses. The article T cell receptor T (TCR-T) cell therapy for solid tumors: challenges and emerging solutions explored the vast potential of TCR-engineered T cells, which can recognize intracellularly derived peptide-MHC complexes and thus target a broader antigenic repertoire than chimeric antigen receptor T (CAR-T) cells. The review discusses combination strategies that integrate TCR-T cells with checkpoint inhibitors, oncolytic viruses, or targeted agents to overcome antigen heterogeneity, T-cell exhaustion, and immunosuppressive microenvironments. Complementing this immunoengineering perspective, Concurrent immune checkpoint blockade for enhanced cancer immunotherapy utilizing engineered hybrid nanovesicles introduced hybrid nanovesicles co-decorated with PD-1 and signaling regulatory protein alpha (SIRPα) receptors to simultaneously disrupt the "don't find me" (PD-1/PD-L1) and "don't eat me" (CD47/SIRPα) signals. In melanoma models, this combinatorial blockade translated into robust antitumor activity and illustrates how multi-receptor targeting on a single nanoplatform can synergistically amplify innate and adaptive immune responses.A second major theme centers on exploiting cancer-specific vulnerabilities in DNA repair and cellcycle regulation. The review Advancing cancer therapy: new frontiers in targeting DNA damage response provides a comprehensive overview of how inhibitors of DNA-PK, ATM, ATR, Wee1 and other DDR kinases can be combined with DNA-damaging agents to induce synthetic lethality. The authors emphasize the importance of genomic and functional biomarkers, such as homologous recombination deficiency signatures, to select patients most likely to benefit from DDR inhibitor-based combinations and to avoid overlapping hematologic and gastrointestinal toxicities. This conceptual framework is further strengthened by the data-driven clinical synthesis Clinical outcomes of DNA-damaging agents and DNA damage response inhibitors combinations in cancer: a data-driven review. By systematically compiling clinical trial outcomes across tumor types, the review delineates where combinations of DDR inhibitors (DDRis) with DNA-damaging agents (DDAs) have achieved meaningful efficacy and where toxicity or lack of stratification has limited success. Together, these two reviews underscore that the future of DDR-based combination therapy lies in rational pairing of agents, careful dose optimization, and biomarker-guided patient selection.Several mechanistic studies in this Topic provide concrete examples of these principles. In Targeting PCNA/PARP1 axis inhibits the malignant progression of hepatocellular carcinoma, inhibition of PCNA was shown to synergize with the PARP inhibitor olaparib by disrupting the PCNA/PARP1 axis, impairing DNA repair and suppressing proliferation and invasion of hepatocellular carcinoma cells. This work highlights a previously underappreciated node of vulnerability that could be exploited in combination with clinically available PARP inhibitors.Similarly, Milciclib-mediated CDK2 inhibition to boost radiotherapy sensitivity in colorectal cancer investigated the role of the cyclin-dependent kinase CDK2 in radioresistance. The authors demonstrate that Milciclib induces G1 arrest, downregulates CDK2 and cyclin E1, and impairs Rad51-mediated DNA repair. When combined with ionizing radiation, Milciclib significantly enhances apoptosis and partially reverses radiation resistance in colorectal cancer cell lines, achieving significant sensitizer enhancement ratios in resistant models. These findings position CDK2 inhibition as a promising approach to resensitize tumors to radiotherapy and exemplify how modulation of cell-cycle checkpoints can be integrated with genotoxic therapies for maximal impact.Antibody-based therapies, including antibody-drug conjugates (ADCs) and recombinant immunotoxins, leverage antigen specificity to improve the therapeutic index of potent cytotoxic payloads. The mini-review Antibody-drug conjugate combinations in cancer treatment: clinical efficacy and clinical study perspectives summarizes how pairing ADCs with immune checkpoint inhibitors, conventional chemotherapy (e.g., taxanes and platinum compounds), or targeted small molecules can overcome resistance mechanisms such as antigen heterogeneity, drug efflux, and adaptive signaling rewiring. The authors highlight emerging clinical evidence that such combinations can deepen responses and extend survival in breast, lung, and urothelial cancers, while underscoring the need for vigilant monitoring of overlapping myelosuppression and neuropathy.In parallel, the review Clinically approved immunotoxins targeting hematological cancers: "the best of both worlds" focuses on recombinant immunotoxins, such as moxetumomab pasudotox and tagraxofusp, which fuse bacterial or plant-derived toxins to antibodies or cytokines that recognize hematologic malignancies. The article discusses combination strategies that incorporate these agents with chemotherapy or hypomethylating drugs to eradicate minimal residual disease, prevent antigen-negative relapse, and achieve deeper remissions in otherwise refractory leukemia and lymphoma.Beyond protein-toxin fusions, innovative radiopharmaceutical combinations add another dimension to this theme. In Iodine-131 induces ferroptosis and synergizes with sulfasalazine in differentiated thyroid cancer cells via suppressing SLC7A11, the authors demonstrate that the radioisotope Iodine-131 not only causes classical radiogenic DNA damage but also triggers ferroptosis by downregulating the cystine transporter SLC7A11. When combined with the ferroptosis inducer sulfasalazine, Iodine-131 produces marked synergistic antitumor effects in thyroid cancer cells. This work illustrates how integrating radiotherapy with regulated cell-death modulators can expand the cytotoxic repertoire beyond apoptosis and necrosis.The incorporation of traditional medicine and naturally derived compounds into modern oncologic regimens provides a critical perspective on modulating both systemic and tumor-specific environments. The systematic review Efficacy and safety of TACE combined with traditional Chinese medicine versus TACE alone in hepatocellular carcinoma: bayesian network metaanalysis and pharmacological mechanisms study offers high-level evidence that adding Traditional Chinese Medicine formulations to transarterial chemoembolization (TACE) significantly improves overall response and disease control rates, prolongs overall survival, and reduces adverse events such as abdominal pain and nausea. Network pharmacology analyses further suggest that multi-component herbal preparations exert pleiotropic effects on angiogenesis, inflammation, and apoptosis, providing a mechanistic rationale for their combination with locoregional chemotherapy. This concept of multi-target, low-toxicity modulation is also showed in the prospective cohort study Enhancing survival outcomes in unresectable hepatocellular carcinoma: a prospective cohort study on the effects of Huaier granules with targeted therapy plus immunotherapy.Here, the addition of Huaier granules to a backbone of targeted therapy plus immunotherapy significantly extended median progression-free survival in unresectable HCC without compromising safety, supporting the feasibility of integrating evidence-based traditional agents into complex systemic regimens.Two research article contributions focus on natural products as chemosensitizers. Chemosensitizing effect of apigenin on T-ALL cell therapy shows that the flavonoid apigenin synergistically enhances the cytotoxic and pro-apoptotic effects of Lasparaginase in T-cell acute lymphoblastic leukemia cells. By modulating oxidative stress, mitochondrial integrity, and pro-survival signaling, apigenin may permit dose reduction of Lasparaginase and thereby alleviate its dose-limiting toxicities. In a solid tumor context, Phytochemical combinations of lichen Evernia prunastri (L.) Ach. reduce drug resistance to temozolomide but not to paclitaxel in vitro highlights that lichen-derived compounds such as evernic acid can restore temozolomide sensitivity in glioblastoma models, likely through modulation of the Wnt signaling pathway and drug efflux mechanisms. These studies collectively suggest that rational incorporation of phytochemicals into conventional chemotherapy regimens may offer a route to overcoming resistance while preserving or even improving tolerability.Modern combination therapy development increasingly depends on innovative delivery platforms and computational tools. The review Nanotechnology-driven strategies in postoperative cancer treatment: innovations in drug delivery systems emphasizes the growing role of local drug delivery systems in the postoperative setting. By implanting or spraying nanomedicine-loaded materials directly into the surgical bed, these approaches can achieve sustained, localized release of chemotherapeutic agents, immune modulators, photothermal and photodynamic sensitizers, and even CAR-T cells. Such strategies have the potential to eradicate residual tumor cells, prevent local recurrence and distant metastasis, reduce systemic toxicity, and simultaneously manage postoperative inflammation and wound healing. This Research Topic emphasizes the shift in oncology towards rational combination therapies. The 19 contributions explore topics such as targeting DDR, inducing ferroptosis, activating the STING pathway, and advancements in nanotechnology, cell therapy, and AI-based drug screening, along with clinical studies on complex treatment regimens (Figure 1). Overcoming resistance requires combining agents with complementary mechanisms and incorporating biomarkers and advanced delivery systems. Key themes include reshaping the tumor microenvironment for immune response, targeting multiple survival pathways, and balancing efficacy with toxicity using natural agents. These efforts aim for durable cancer control, supported by interdisciplinary collaboration and emerging technologies in precision medicine.